CarsonAllaria Wealth Management Ltd. lessened its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 827 shares of the medical research company’s stock after selling 91 shares during the period. CarsonAllaria Wealth Management Ltd.’s holdings in Amgen were worth $259,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of the business. Provence Wealth Management Group grew its holdings in shares of Amgen by 11.9% in the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. boosted its position in shares of Amgen by 33.0% during the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after acquiring an additional 2,814 shares in the last quarter. Global Wealth Management Investment Advisory Inc. increased its holdings in shares of Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after acquiring an additional 109 shares during the last quarter. Valley Brook Capital Group Inc. boosted its holdings in Amgen by 7.0% in the fourth quarter. Valley Brook Capital Group Inc. now owns 4,730 shares of the medical research company’s stock valued at $1,362,000 after purchasing an additional 310 shares in the last quarter. Finally, Evergreen Wealth Management LLC increased its stake in Amgen by 1.7% in the fourth quarter. Evergreen Wealth Management LLC now owns 4,892 shares of the medical research company’s stock valued at $1,409,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Price Performance
AMGN traded up $0.58 during midday trading on Tuesday, reaching $328.55. 1,352,484 shares of the company’s stock were exchanged, compared to its average volume of 2,599,579. Amgen Inc. has a one year low of $248.38 and a one year high of $346.85. The firm has a market capitalization of $176.25 billion, a price-to-earnings ratio of 46.94, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. The business has a 50-day simple moving average of $321.01 and a two-hundred day simple moving average of $299.19. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.
Analysts Set New Price Targets
Several analysts have recently weighed in on the company. Mizuho boosted their target price on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Bank of America lifted their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $230.00 to $300.00 in a research note on Friday, May 3rd. Morgan Stanley lowered their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Finally, StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $326.89.
Get Our Latest Research Report on Amgen
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- Stock Market Sectors: What Are They and How Many Are There?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Investing in Construction Stocks
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.